The access environment in 2026 is defined by pressure from every direction at once. Policy volatility, restrictive payer management, affordability challenges, and the accelerating automation of payer decision-making are no longer sequential problems — they’re converging simultaneously, compressing manufacturers’ options and reshaping how access is won.
To keep pace with this shifting landscape, MMIT and The Dedham Group conducted our third annual State of Patient Access Survey, gathering insights from 285 pharma and biotech leaders across commercial strategy, medical affairs, and managed markets. Here, authors Hannah Baxter and Andrew Rouff share what the data reveals about how manufacturers are responding — and what it will take to secure access for patients in an environment where the rules are being rewritten in real time.
RESEARCH REPORT
The State of Patient Access 2026
Authors Hannah Baxter and Andrew Rouff take a deep dive into the survey results to better understand today’s evolving market access landscape.
WEBINAR
Navigating Policy and Pricing Pressures
In this webinar, hosted by Biopharma Dive, the authors explore industry trends and share how brands are responding to these converging pressures.
EXECUTIVE SUMMARY
Navigating Policy and Pricing Pressures
Review the most compelling survey findings—and key expert insights—shared in the Biopharma Dive webinar.
Infographic
The AI Access Gap
Payers are automating utilization management at scale, while manufacturers are using AI to identify access barriers earlier in the patient journey.
INFOGRAPHIC
The Rise of Direct-to-Consumer: Pharma's Path Around the Formulary
As payer restrictions and biosimilar competition intensify, manufacturers are turning to cash-pay DTC programs as a new way to reach patients.
